Defence Therapeutics Inc. | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55332	Articles
62460	Press releases

Headlines Articles Press releases Defence Therapeutics Inc.

Home
Companies
Defence Therapeutics Inc.

BRIEF

published on 06/25/2024 at 08:05, 4 months 26 days ago

Defence's ARM-X Vaccine Shows Promising Results Against Ovarian Cancer in Pre-Clinical Trials

Defence Therapeutics Ovarian Cancer Immune-oncology ARM-X Pre-clinical Studies
PRESS RELEASE

published on 06/25/2024 at 08:00, 4 months 26 days ago

DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
Defence Therapeutics Inc. announces successful inhibition of ovarian cancer growth with ARM-X anti-cancer vaccine and anti-PD-1 combination therapy in pre-established cancer models

Defence Therapeutics Inc. Ovarian Cancer Immune-oncology Anti-PD-1 ARM-X Vaccine
BRIEF

published on 06/17/2024 at 08:05, 5 months 4 days ago

Defence Therapeutics Inc. Highlights ACCUM Platform for Cancer Treatments

Biopharmaceutical Defence Therapeutics Cancer Treatments ACCUM Platform Dr. Moutih Rafei
PRESS RELEASE

published on 06/17/2024 at 08:00, 5 months 4 days ago

DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
Defence Therapeutics Inc.'s Chief Scientific Officer Dr. Moutih Rafei discusses the ACCUM platform for cancer treatments on Money Talk Radio with Ellis Martin

Defence Therapeutics Inc. Cancer Treatments ACCUM Platform Dr. Moutih Rafei Money Talk Radio
BRIEF

published on 06/10/2024 at 08:05, 5 months 11 days ago

Defence Therapeutics to Attend 2024 SNMMI Annual Meeting in Toronto

Defence Therapeutics Nuclear Medicine SNMMI AccuTRIC™ Molecular Imaging
PRESS RELEASE

published on 06/10/2024 at 08:00, 5 months 11 days ago

DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
Defence Therapeutics Inc. to participate in the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024, presenting their novel Radio-Immuno-Conjugate (RIC) for cancer treatment

Cancer Treatment Defence Therapeutics Inc. Molecular Imaging Society Of Nuclear Medicine Radio-Immuno-Conjugate
BRIEF

published on 06/06/2024 at 08:05, 5 months 15 days ago

Defence Therapeutics' AccuTOX Study Published in Journal of Translational Medicine

Clinical Trials Immunotherapy Defence Therapeutics AccuTOX Anti-cancer
PRESS RELEASE

published on 06/06/2024 at 08:00, 5 months 15 days ago

DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Defence Therapeutics Inc.'s AccuTOX published in the prestigious Journal of Translational Medicine along with preclinical data on AccuTOX as an anti-cancer molecule. Study highlights AccuTOX's superior therapeutic properties and versatility for different cancer treatments

Preclinical Data Defence Therapeutics Inc. AccuTOX Journal Of Translational Medicine Anti-cancer Molecule
BRIEF

published on 05/14/2024 at 08:05, 6 months 7 days ago

Defence Therapeutics Expands Patent Portfolio Globally

Defence Therapeutics Patent Issuance Drug Delivery System Innovation In Healthcare Immune-Oncology Vaccine
PRESS RELEASE

published on 05/14/2024 at 08:00, 6 months 7 days ago

DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Defence Therapeutics strengthens and expands global patent protection on key technologies, including vaccine enhancer platform and ADC platform technology. The new patents and allowances showcase the company's commitment to innovation in biopharmaceuticals

Biopharmaceuticals Defence Therapeutics Patent Protection Vaccine Enhancer ADC Platform Technology

Accesswire

Published on 11/21/2024 at 13:30, 15 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 15 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 45 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 45 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 45 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 30 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 10 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 30 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 39 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 45 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 47 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 25 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE